The free guide available below discusses upcoming changes in the use of skin substitute grafts and cellular and/or tissue-based products for the treatment of diabetic foot ulcers and venous leg ulcers. These changes will take effect on or after 10/1/2023, impacting several Medicare Administrative Contractors (MACs) including CGS, First Coast, and Novitas. Notable changes include … Continued
Read Part 1 The upcoming changes CMS is proposing on CTPs in regards to the treatment of Diabetic Foot Ulcers and Venous Leg Ulcers may have an impact for wound care programs on Medicare coding, coverage, and reimbursement. However, knowing what those changes are and what it means for wound care programs is sometimes unclear. … Continued
Read Part 2 Throughout the recent talk of the changes Centers for Medicare & Medicaid Services (CMS) have proposed in regards to Cellular Tissue-Based Products (CTP’s), concerns have been raised in the current gaps of education and documentation needs with these products across the nation. In discussions about what CMS is proposing, industry leaders break … Continued